Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Frontiers in Pharmacology|September 5, 2022
Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysisSalomé Martin, Brahim Azzouz, Aurore Morel, et al.
Expert Opinion on Drug Safety|December 18, 2020
Drug induced stuttering: pharmacovigilance dataThierry Trenque, Aurore Morel, Agathe Trenque, et al.
Expert Opinion on Drug Safety|August 4, 2018
Psoriasis during angiotensin receptor blocker exposure: an underestimated adverse drug reactionBrahim Azzouz, Malak Abou Taam, Aurore Morel, et al.
European Journal of Clinical Pharmacology|January 7, 2022
Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entityThierry Trenque, Elise Lepoix, Agathe Trenque, et al.
Drug Safety|October 11, 2019
Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the LiteratureBrahim Azzouz, Aurore Morel, Lukshe Kanagaratnam, et al.
British Journal of Clinical Pharmacology|August 9, 2023
Drug-induced Sweet's syndrome: A case/non-case study in the French pharmacovigilance databaseSalomé Martin, Thierry Trenque, Emmanuelle Herlem, et al.
Therapie|January 14, 2022
Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitalsQuentin Jarrion, Brahim Azzouz, James Robinson, et al.
Therapie|August 25, 2023
Statins and immune-mediated necrotizing myopathy: Variability in the riskThierry Trenque, Jed Hadjoudj, Agathe Trenque, et al.
Therapie|May 24, 2018
Eosinophilic pneumonia induced by non-steroidal anti-inflammatory drugs: An underestimated riskFrançois Krabansky, Brahim Azzouz, Josette Biya, et al.
British Journal of Clinical Pharmacology|March 30, 2022
Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signalBrahim Azzouz, Apolline De Guizelin, Aude Lambert, et al.
Pageof 2